[1]. Suerie Moon. Respecting the Right to Access to M to edicines: Implications of the UN Guiding Principles on Business and Human Rights for the Pharmaceutical Industry. Health and Human Rights, Volume 15, No. 1, June 2013; P 33.
[1]. Obijiofor Aginam & Others. The Global Governance of HIV/AIDS: Intellectual Property and Access to Essential Medicines. Edward Elgar Publishing, Inc. 2013; P 59.
https://doi.org/10.4337/9781849804929
[1]. Hestermeyer H. Human rights and the WTO: the case of patents and access to medicines. Oxford University Press; 2008 Aug 7.
[1]. UN Economic and Social Council, General Comment No. 14: The Right to the Highest Attainable Standard of Health (Art. 12 of the Covenant), E/C.12/2000/4, UN Committee on Economic, Social and Cultural Rights (CESCR), 11 August 2000, https://www.refworld.org/legal/general/cescr/2000/en/36991 [accessed 09 August 2024]
[1]. Secretary-General UN. Access to medication in the context of pandemics such as HIV/AIDS, tuberculosis and malaria: report of the Secretary-General.2008.
[1]. World Health Organization, ‘Essential Medicines: Definition’, available at http://www.who. int/medicines/services/essmedicines_def/en/. See also MDG Gap Task Force, Millennium Development Goal 8: Delivering on the Global Partnership for Achieving the Millennium Development Goals: MDG Gap Task Force Report 2008 (New York: United Nations, 2008) at 36.
[1]. Marks SP. Access to essential medicines as a component of the right to health. Realizing the right to health. Zurich, Switzerland: Rüfer and Rub. 2009:82-101.
[1]. World Health Organization, World Bank. Tracking universal health coverage: first global monitoring report [Internet]. Geneva; 2015. [cited 2019 February13]
[1]. Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, Gyansa-Lutterodt M, Jing S, Luiza VL, Mbindyo RM, Möller H. Essential medicines for universal health coverage. The Lancet. 2017 Jan 28;389(10067):403-76.
[1]. Mahmić-Kaknjo M, Jeličić-Kadić A, Utrobičić A, Chan K, Bero L, Marušić A. Essential medicines availability is still suboptimal in many countries: a scoping review. Journal of clinical epidemiology. 2018 Jun 1;98:41-52.
[1]. Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, Wei L, Mony P, Mohan V, Gupta R, Kumar R. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. The Lancet. 2016 Jan 2;387(10013):61-9.
[1]. Hogerzeil HV, Liberman J, Wirtz VJ, Kishore SP, Selvaraj S, Kiddell-Monroe R, Mwangi-Powell FN, von Schoen-Angerer T. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. The Lancet. 2013 Feb 23;381(9867):680-9.
[1]. Forouzandeh Zarenezhad & Others. Developing a Model for Agile Pharmaceutical Distribution: Evidence from Iran. J. Basic. Sci. Res., 3(1)161-172, 2013; P 161.
[1]. Abdol Majid Cheraghali. Iran Pharmaceutical Market. Iranian Journal of Pharmaceutical Research, 2006, 1-7, P 2.
[1]. Michel Belanger. Global Health Law: An Introduction. Cambridge Scientific Publishers, 2011; P 89.
[1]. Allen Buchanan. Justice and Health Care: Selected Essays: 2009; P 203-206.
[1]. John Tobin. The Right to Health in International Law. Oxford University Press, 2012; P 159-161.
[1]. Christopher Stone. Resource Allocation and Rationing Strategies in the NHS, 2010; P 1.
[1]. Jakkrit Kuanpoth. Patent Rights in Pharmaceuticals in Developing Countries: Major Challenges for Future. Edward Elgar Publishing, Inc. 2010; P 163.
https://doi.org/10.4337/9781849808958
[1]. Gillian LewandoHundt & Others. The Provision of Acceptable Health Care in Rural Remote Areas and the Right to Health: Bedouin in the North East Region of Jordan. Social Science & Medicine. Social Science & Medicine 74(2012) 36-43.
https://doi.org/10.1016/j.socscimed.2011.08.042 . PMid:22024202
[1]. Irina Haracoglou. Comprtition Law and Patents: A Follow-on Innovation Perspective in the Biopharmaceutical Industry. Edward Elgar Publishing, Inc, 2007; P 78.
https://doi.org/10.4337/9781848440111
[1]. Hans V. Hogerzeil & Zafar Mirza. The World Medicines Situation 2011: Access to Essential Medicines as Part of the Right to Health. World Health Organization, 2011; P 4.
[1]. WHO & Kenya’s Ministry of Public Health & Ministry of Medical Services. Kenya Essential Medicines List 2010, 2010; P xiv.
[1]. World Health Organization. Essential Drugs Monitor. Number 33 (2003).
[1]. Richard Laing. The Patent Status of Medicines on the WHO Model List of Essential Medicines. WHO/WTO/WIPO Technical Symposium. 2011;
[1]. Kyla Hyford & Others. Improving Access to Essential Medicines Through Public-Private Partnerships. International Vaccine Access Center (IVAC), 2004; P 1.
[1]. Ghana’s Ministry of Health. Ghana Essential Medicines List. Sixth Edition, 2010; P Introduction.
[1]. Brian M. Kaiser. World Health Organization’s Essential Medicines List: From Idea to Implementation. Prepared as Part of an Education project of the Global Health Education Consortium and Collaborating Partners. 2007; P 5.
[1]. Alison Sinton. WHO Essential Medicines Process. Splaine Consulting WHO Essential Medicines Brief, 2014; P 2.
[1]. Cythia M. Ho. Access to Medicine in the Global Economy. Oxford University Press, 2011; P 5.
[1]. Ronald J. Vogel. Pharmaceutical Economics and Public Policy. Routledge, Jul 2007; P 27.
[1]. OECD Health Policy Studies. Pharmaceutical Pricing Policies in a Global Market. OECD Publishing, 2008; P 97.
[1]. Kavoos Basmenji Pharm D. Pharmaceuticals in Iran: An Overview (History of Contemporary Medicine in Iran). Arch Iranian Med 2004; 7(2): 158- 164. P 159.
[1]. Sheikhi M. Challenges of Intellectual Property in the Field of Health. Social Welfare Quarterly. 2006; 5 (20): 61.
[1]. Kheirollah Gholami & Others. Three Years Evaluation of Drug Shortages from Educational Pharmacies in Tehran. Iranian Journal of Pharmaceutical Research .2012, 11 (2): 565-572. P 565.
[1]. Houda I, Dickhoff C, Uyl-de Groot CA, Reguart N, Provencio M, Levy A, Dziadziuszko R, Pompili C, Di Maio M, Thomas M, Brunelli A. New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe. The Lancet Regional Health–Europe. 2024 Mar 1;38.
[1] .Volodina A, Jahn A, Jahn R. Public health relevance of medicines developed under paediatric legislation in Europe and the USA: a systematic mapping study. BMJ Paediatrics Open. 2024;8(1).
[1] .Liu M, Lu Y, Li J, Zhang Y, Zhang S, Liu Y. Orphan drug policy analysis in China. Frontiers in Pharmacology. 2024 Jun 13;15:1278710.
[1] .Cordeiro MA, Vitorino C, Sinogas C, Sousa JJ. A Regulatory Perspective on Biosimilar Medicines. Pharmaceutics. 2024 Feb 25;16(3):321.
[1]. Piggott T, Moja L, Garcia CA, Akl EA, Banzi R, Huttner B, Kredo T, Lavis JN, Schünemann HJ. User-experience testing of an evidence-to-decision framework for selecting essential medicines. PLOS Global Public Health. 2024 Jan 11;4(1):e0002723.
[1]. Chejor P, Dorji T, Dema N, Stafford A. Good manufacturing practice in low‐and middle‐income countries: Challenges and solutions for compliance. Public Health Challenges. 2024;3(1): e158.
[1]. Ortiz-Millán G. Ethical and Practical Considerations for an Agreement to Ensure Equitable Vaccine Access; Comment on “More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap”. International Journal of Health Policy and Management. 2024 Apr 28.
[1]. Amin MQ, Kristina SA, Satibi S. Availability, prices, and affordability of essential medicines in Asia: A systematic review. Journal of Applied Pharmaceutical Science. 2024 May 24.
[1]. Sorato MM, Davari M, Kebriaeezadeh A. Improving access to medicines to reduce marketing and use of substandard and falsified medicines in Africa: Scoping review. The Journal of Medicine Access. 2024 Mar;8:27550834241236598.
[1]. Quick JD. Essential medicines twenty-five years on: closing the access gap. Health policy and planning. 2003 Mar 1;18(1):1-3.
[1]. Hogerzeil HV. Essential medicines and human rights: what can they learn from each other?. Bulletin of the World Health Organization. 2006;84:371-5.
[1]. Mackintosh M, Mujinja PG. Markets and policy challenges in access to essential medicines for endemic disease. Journal of African Economies. 2010 Nov 1;19(suppl_3):iii166-200.
[1]. Chivukula MV, Tisocki K. Approaches to improving access to essential cancer medicines in the WHO South-East Asia Region. WHO South-East Asia journal of public health. 2018 Sep 1;7(2):62-6.
[1]. Abbott FM. Managing the hydra: the Herculean task of ensuring access to essential medicines. International Public Goods and Transfer of Technology after Trips. 2004 Dec 21:393-424.
[1]. on Neuroscience F, Disorders NS. Improving Access to Essential Medicines for Mental, Neurological, and Substance Use Disorders in Sub-Saharan Africa: Workshop Summary.
)